Home / Business and Economy / CME Group Faces Regulator Showdown
CME Group Faces Regulator Showdown
18 Jun
Summary
- Investment firm upgrades CME Group shares, citing attractive risk/reward.
- CME Group plans to sue regulators over perpetual futures contracts approval.
- Analysts remain largely positive on CME Group stock despite regulatory issues.
Investment firm Keefe, Bruyette & Woods has upgraded CME Group, advising investors to buy shares while they are trading at a discount. The firm set a $305 price target, indicating potential for 21% upside. Analyst Chris Allen believes recent stock declines are driven by exaggerated fears regarding perpetual futures, noting CME's limited retail exposure and equity product licenses mitigate these risks.
Despite a year-to-date decline of nearly 8%, CME Group is preparing to challenge the Commodity Futures Trading Commission (CFTC) in court. The company plans to sue the CFTC over its approval of perpetual futures contracts. CME Group CEO Terry Duffy stated the litigation is necessary to clarify the law, emphasizing the company's stance is not personal but based on legal interpretation.
This optimistic outlook aligns with broader Wall Street sentiment. Out of 17 analysts covering CME Group, 8 currently recommend a buy or strong buy, reflecting confidence in the company's future performance.
